Share ownership Formycon AG

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 16:35:16 10/02/2026 GMT			5-day change	1st Jan Change
23.50 ^EUR	+1.08%		+2.84%	-8.20%

12-23	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar	MT
12-23	Formycon AG - FDA approves biologics license application (BLA) for additional ranibizumab biosimilar under trade name Nufymco	RE

Share class: Formycon AG

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	17,664,427	11,193,953 ( 63.37 %)	0	63.37 %

Major shareholders: Formycon AG

Name	Equities	%	Valuation
Struengmann Family 24.03 %	4,246,528	24.03 %	116 M €
Wendeln & Cie. KG 13.24 %	2,340,537	13.24 %	64 M €
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt. 9.075 %	1,603,877	9.075 %	44 M €
Active Ownership Corp SARL 6.037 %	1,066,931	6.037 %	29 M €
Detlef Spruth 5.094 %	900,206	5.094 %	25 M €
Stefan Reichensperger 3.277 %	579,133	3.277 %	16 M €
Paladin Asset Management Investmentaktiengesellschaft TGV 0.2483 %	43,876	0.2483 %	1 M €
GS&P Kapitalanlagegesellschaft SA 0.1839 %	32,500	0.1839 %	889 263 €
Joh. Berenberg, Gossler & Co. KG (Investment Management) 0.1471 %	26,000	0.1471 %	711 411 €
Aktia Varainhoito Oy 0.1441 %	25,471	0.1441 %	696 936 €
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	32.4%
Other	22.32%
Institutional	7.08%
Unknown	38.2%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	32.4%
Germany	13.9%
Hungary	9.08%
Luxembourg	6.28%
Finland	0.14%
Ireland	0.01%

Based on 1000 largest holdings

Formycon AG is a Germany based Company. The Company is engaged in providing biosimilar drugs and formulations. The Company focuses on treatments in ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval.

Employees

250

Sector

Biotechnology & Medical Research

Calendar

04-22 - Q4 2025 Earnings Release (Projected)

More about the company